Free Trial

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Position Lifted by GSA Capital Partners LLP

Vanda Pharmaceuticals logo with Medical background

GSA Capital Partners LLP increased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 88.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 260,215 shares of the biopharmaceutical company's stock after acquiring an additional 121,797 shares during the period. GSA Capital Partners LLP owned approximately 0.44% of Vanda Pharmaceuticals worth $1,194,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Quantinno Capital Management LP acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $48,000. Linden Thomas Advisory Services LLC acquired a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $49,000. XTX Topco Ltd acquired a new position in Vanda Pharmaceuticals during the fourth quarter valued at approximately $69,000. Zacks Investment Management purchased a new stake in Vanda Pharmaceuticals during the fourth quarter worth approximately $74,000. Finally, ProShare Advisors LLC increased its position in shares of Vanda Pharmaceuticals by 32.4% in the fourth quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 4,599 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VNDA has been the topic of several recent research reports. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Get Our Latest Stock Report on VNDA

Vanda Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ VNDA traded down $0.07 during trading on Friday, reaching $4.19. 766,997 shares of the stock were exchanged, compared to its average volume of 577,715. The company has a market capitalization of $246.92 million, a price-to-earnings ratio of -5.59 and a beta of 0.68. The business's 50-day moving average price is $4.64 and its 200 day moving average price is $4.54. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $5.56.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). The firm had revenue of $52.59 million during the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative return on equity of 8.30%. As a group, sell-side analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 20,000 shares of the company's stock in a transaction on Friday, May 16th. The shares were bought at an average cost of $4.22 per share, for a total transaction of $84,400.00. Following the acquisition, the chief executive officer directly owned 2,315,731 shares of the company's stock, valued at $9,772,384.82. This trade represents a 0.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen Ray Mitchell sold 7,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the transaction, the director directly owned 97,082 shares in the company, valued at approximately $445,606.38. The trade was a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.00% of the company's stock.

Vanda Pharmaceuticals Profile

(Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Read More

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Should You Invest $1,000 in Vanda Pharmaceuticals Right Now?

Before you consider Vanda Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.

While Vanda Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines